A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Trial Details

NCT ID

NCT06839105

Phase

PHASE1

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

• Taxol
• Cisplatin or Carboplatin
• Pemetrexed
• Oxaliplatin
• Capecitabine
• Bevacizumab

Locations (sample)

• Fuzhou, Fujian, China|26.06139,119.30611
• Guangzhou, Guangdong, China|23.11667,113.25
• Harbin, Heilongjiang, China|45.75,126.65
• Luoyang, Henan, China|34.67345,112.43684
• Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

• Both male and female subjects who are at least 18 years old at the time of signing the consent form;
• Inclusion of patients with advanced malignancies confirmed histologically or cytologically and meeting the following requirements:
• Single-agent dose escalation and expansion phase to include patients with advanced malignant tumors who have failed or are intolerant of standard t…
• Therapeutic effect expansion stage of single drug:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.